Inhibiting PD-L1 allowed for further functioning of T cells via anti-EGFR-hmLIGHT within the Ag104Ld and MC38 tumor models, inducing complete rejection of established tumors in a therapeutic setting. This evidence concerns the gene CD274 and neoplasm.